Top Abstract Purchase Related
Home
>
Node
>
Subnode

Effect of avitaminosis a and hypervitaminosis a on urinary bladder carcinogenicity of N- (4- (5-Nitro-2-furyl) -2-thiazolyl) formamide

Cohen, S.M.; Wittenberg, J.F.; Bryan, G.T.

Cancer Research 36(7 Part 1): 2334-2339

1976

ISSN/ISBN: 0008-5472
PMID: 1277139
Document Number: 98051
The effect of vitamin A deficiency and hypervitaminosis A on the urothelial carcinogenicity of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formanmide (FANFT) was determined in female weanling Sprague-Dawley rats. Vitamin A deficiency resulted in squamous metaplasia of the urinary bladder and high incidences of cystitis, ureteritis, and pyelonephritis. Administration of FANFT to vitamin A-deficient rats appeared to accelerate the carcinogenic process, with earlier appearance of urinary bladder tumors and the development of ureteral and renal pelvic carcinomas. Most of these tumors were squamous cell, occasionally with transitional cell foci. Hypervitaminosis A prevented the appearance of squamous metaplasia and squamous cell neoplasia in rats fed FANFT, but it did not inhibit the formation of transitional cell hyperplasia or neoplasia in comparison to rats receiving normal levels of vitamin A and FANFT.

Document emailed within 1 workday
Secure & encrypted payments

Rice, J.R.; Spry, L.A.; Zenser, T.V.; Davis, B.B. 1988: Effect of peroxidase inhibitors on an in vivo metabolite of the urinary bladder carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in rats Cancer Research 48(2): 304-309
Sakata, T.; Hasegawa, R.; Johansson, S.L.; Zenser, T.V.; Cohen, S.M. 1986: Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats Cancer Research 46(8): 3903-3906
Cohen, S.M.; Zenser, T.V.; Murasaki, G.; Fukushima, S.; Mattammal, M.B.; Rapp, N.S.; Davis, B.B. 1981: Aspirin inhibition of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced lesions of the urinary bladder correlated with inhibition of metabolism by bladder prostaglandin endoperoxide synthetase Cancer Research 41(9 Part 1): 3355-3359
Tiltman, A.J. 1972: The use of N-(4-(5-nitro-2-furyl)-2-thiazolyl) formamide in the study of bladder cancer South African Medical Journal 46(11): 293-294
Masui, T.; Mann, A.M.; Macatee, T.L.; Okamura, T.; Garland, E.M.; Fujii, H.; Pelling, J.C.; Cohen, S.M. 1991: H-ras mutations in rat urinary bladder carcinomas induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide and sodium saccharin, sodium ascorbate, or related salts Cancer Research 51(13): 3471-3475
Niell, H.B.; Wood, C.A.; Mickey, D.D.; Soloway, M.S. 1982: Time- and concentration-dependent inhibition of the clonogenic growth of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced murine bladder tumor cell lines by cis-diamminedichloroplatinum(II) Cancer Research 42(3): 807-811
Zenser, T.V.; Mattammal, M.B.; Davis, B.B. 1980: Metabolism of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide by prostaglandin endoperoxide synthetase Cancer Research 40(1): 114-118
Morton, K.C.; Wang, C.Y. 1983: Enhanced macromolecular binding of N-[4-(5-nitro-2-furyl)-2-thiazolyl]- formamide in germfree versus conventional rats Cancer Research 43(8): 3628-3632
Ertürk, E.; Morris, J.E.; Cohen, S.M.; Von Esch, A.M.; Crovetti, A.J.; Price, J.M.; Bryan, G.T. 1971: Comparative carcinogenicity of formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide and related chemicals in the rat Journal of the National Cancer Institute 47(2): 437-445
Ertürk, E.; Morris, J.E.; Cohen, S.M.; Price, J.M.; Bryan, G.T. 1970: Transplantable rat mammary tumors induced by 5-nitro-2-furaldehyde semicarbazone and by formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl] hydrazide Cancer Research 30(5): 1409-1412
Wise, R.W.; Zenser, T.V.; Davis, B.B. 1983: Peroxidase metabolism of the urinary bladder carcinogen 2-amino-4-(5-nitro-2-furyl)thiazole Cancer Research 43(4): 1518-1522
Cohen, S.M.; Headley, D.B.; Bryan, G.T. 1973: The effect of adult thymectomy and adult splenectomy on the production of leukemia and stomach neoplasms in mice by N-(4-(5-nitro-2-furyl)-2-thiazolyl)acetamide Cancer Research 33(4): 637-640
Mattammal, M.B.; Zenser, T.V.; Palmier, M.O.; Davis, B.B. 1985: Renal reduced nicotinamide adenine dinucleotide phosphate:cytochrome c reductase-mediated metabolism of the carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]acetamide Cancer Research 45(1): 149-156
Holla, B.S.; Shivananda, M.K.; Akberali, P.M.; Baliga, S.; Safeer, S. 1996: Studies on arylfuran derivatives-Part VI. Synthesis, characterization and antibacterial activities of some 6-(5-aryl-2-furyl)-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazoles and 6-(5-nitro-2-furyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles Farmaco 51(12): 785-792
Tekeli, S.; Biava, C.G.; Price, J.M. 1973: The carcinogenic activity of 3-hydroxymethyl-1-((3-(5-nitro-2-furyl)allydidene)amino)-hydantoin in rats Cancer Research 33(11): 2894-2897
Tracy, J.W.; Catto, B.A.; Webster, L.T. 1991: Formation of N-(5-nitro-2-thiazolyl)-N'-carboxymethylurea from 5-hydroxyniridazole. Role of aldehyde dehydrogenase in the oxidative metabolism of niridazole Drug Metabolism and Disposition: the Biological Fate of Chemicals 19(2): 508-515
Mattammal, M.B.; Zenser, T.V.; Davis, B.B. 1981: Prostaglandin hydroperoxidase-mediated 2-amino-4-(5-nitro-2-furyl) [14C]thiazole metabolism and nucleic acid binding Cancer Research 41(12 Part 1): 4961-4966
Ertürk, E.; Cohen, S.M.; Bryan, G.T. 1970: Induction, histogenesis, and isotransplanta bility of renal tumors induced by formic acid 2-[4-(5-nitro-2-furyl)-2-triazolyl]-hydrazide in rats Cancer Research 30(8): 2098-2106
Svet-Moldavskiĭ, G.I.; Turusov, V.A.; Osipova, T.V. 1975: Transplantable cancer of the urinary bladder and hemangiopericytoma obtained by means of the ectopic transplantation of tissues of the fetal urinary bladder Voprosy Onkologii 21(9): 89-93
Nishino, T.; Katayama, K.; Takahashi, Y.; Tanaka, T. 2012: A case of sigmoid colon cancer invading urinary bladder treated with preoperative mFOLFOX6 and urinary bladder conserving surgery Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(2): 301-304